ABVC Biopharma, Inc. entered into a definitive agreement with OncoX BioPharma, Inc. to grant them exclusive rights to develop and commercialize ABVC's single-herb botanical drug extract for the treatment of Non-Small Cell Lung Cancer in North America for 20 years, in exchange for $6,250,000 and royalties based on net sales.